Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab-irmb) has been approved by the US Food and Drug ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration ... INDICATION LEQEMBI ® [(lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of ...

Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...

Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular ...

The products already have warnings of immediate post-injection reaction, chest pain, localised fat loss, and immune response modification, as per the drugs’ labels. Teva Pharmaceutical’s Copaxone was ...

Biogen shares soared 44% on a single day in ... The company is also evaluating a follow-on drug, known as remternetug, via injection as well as infusion. The late-stage trial will assess the ...

She advises against touching, rubbing, or massaging the treated area for about 24 hours and to avoid working for about 48 hours post-injection. While most will start to notice the appearance of ...